Ligand Spins Out and Merges Pelican Subsidiary with Primordi

Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biologyLigand contributes $15 million in exchange for economic interest in select Primrose programsLigand improves cash expense outlook and raises EPS guida...

Related Keywords

India , Primrose Bio , Simon Latimer , Todd Davis , Alvogen Teriparatide , Bob Yedid , Pfenex Expression Technology , Exchange Commission , Ligand Pharmaceuticals Incorporated , Amgen , Serum Institute Of India , Primrose Bio Inc , Pelican Expression Technology , Pelican Holdings Inc , Pelican Technology Holdings Inc , Ligand Pharmaceuticals , Jazz Pharmaceuticals , Gilead Sciences , Serum Institute Of India Pneumosil , Genetics Inc , Pfizer , Ligand Pelican Expression Technology , Baxter International , Pelican Technology Holdings , Primordial Genetics , Pelican Expression , Sale Agreement , Primordial Genetic Function Generator , Pfenex Expression , Serum Institute , Function Generator , Pelican Holdings , Private Securities Litigation Reform Act ,